Clinical Trials
6 trialsNCT04840602 2026-05-27
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07420959 2026-02-19
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT00088881 2017-05-25
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00769288 2014-01-07
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00504205 2013-08-02
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
National Cancer Institute (NCI)
Phase NA Terminated